Scienture Holdings, Inc. SCNX
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
4/9
Piotroski F — financial health
-0.88
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $431,609 | -$41.5M | $331,482 | — | $70.1M |
| 2024 | $136,643 | $9.1M | $6,005 | -$13.3M | $79.1M |
| 2023 | $1.4M | -$17.8M | $49,030 | — | $542,353 |
| 2022 | $10.3M | -$3.5M | $5.5M | — | $342,867 |
| 2021 | $9.9M | -$5.3M | $4.7M | -$2.6M | $3.8M |
| 2020 | $17.1M | -$2.5M | $5.7M | -$2.3M | $8.7M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Shankar Hariharan | Co-CEO & Chairman | 2026-02-20 | Grant | 500,000 | — |
| Narasimhan Mani | President & Co-CEO | 2026-02-20 | Grant | 500,000 | — |
| Narasimhan Mani | President & Co-CEO | 2025-10-01 | Grant | 300,000 | — |
| Shankar Hariharan | Co-CEO & Chairman | 2025-10-01 | Grant | 300,000 | — |
| Shankar Hariharan | Co-CEO & Chairman | 2025-04-14 | Grant | 750,000 | — |
| Narasimhan Mani | President & Co-CEO | 2025-04-14 | Grant | 750,000 | — |
| Shankar Hariharan | Co-CEO & Chairman | 2025-03-10 | J | 30,000 | — |
| Narasimhan Mani | President & Co-CEO | 2025-03-10 | J | 20,000 | — |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -0.88 (distress)
- Working capital / assets 0.062
- Retained earnings / assets -0.957
- EBIT / assets -0.506
- Equity / liabilities 4.988
Source: SEC EDGAR filings · CIK 0001382574 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.